林 佩瑩

Medicine & Life Sciences

1. Neoplasms 100%
2. Nucleotide Aptamers 94%
3. Lung Neoplasms 84%
4. Survival 75%
5. Adenocarcinoma of Lung 73%
6. Taiwan 70%
7. collapsin response mediator protein-1 64%
8. Gastrointestinal Tuberculosis 57%
9. Meta-Analysis 48%
10. Lower Gastrointestinal Tract 46%
11. Non-Small Cell Lung Carcinoma 45%
12. CTLA-4 Antigen 45%
13. Neoplasm Metastasis 44%
14. Aggregatibacter actinomycetemcomitans 43%
15. Neglected Diseases 43%
16. Gastrointestinal Neoplasms 42%
17. Immunotherapy 42%
18. MicroRNAs 38%
19. Acute Liver Failure 37%
20. Survival Analysis 37%
21. Cholangiocarcinoma 37%
22. Acute Lung Injury 36%
23. Dimerization 36%
24. Untranslated RNA 36%
25. Progression-Free Survival 34%
26. Squamous Cell Carcinoma 33%
27. Epithelial-Mesenchymal Transition 33%
28. United States Food and Drug Administration 32%
29. Clinical Trials 30%
30. Cohort Studies 30%
31. Human Influenza 29%
32. Chronic Obstructive Pulmonary Disease 28%
33. Parkinson Disease 27%
34. Lung 26%
35. Vaccination 25%
36. Phosphotransferases 25%
37. Necrosis 24%
38. Carcinogenesis 24%
39. Hospitalization 23%
40. Systematic Reviews 23%
41. Confidence Intervals 23%
42. Genes 23%
43. Lymph Nodes 23%
44. Breast Neoplasms 22%
45. Ligands 22%
46. Publications 22%
47. Survivors 22%
48. Thorax 22%
49. Antibodies 22%
50. Biomarkers 21%